Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Institut Gustave Roussy · Szpital Uniwersytecki w Krakowie · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
2,222
total citations
- FWCI
- 147.31
- Percentile
- 100%
- References
- 55
Citations per year
Authors
15Topics & keywords
Topics
Keywords
- Medicine
- Bevacizumab
- Interim analysis
- Clinical endpoint
- Renal cell carcinoma
- Internal medicine
- Interferon alfa
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.